Abingdon Health, a medical device manufacturer with premises in Doncaster, York and Birmingham has received key approval for its Covid-19 rapid antibody test.
The company, which is leading the UK-Rapid Test Consortium (UK-RTC), has received its CE mark, meaning the test is approved for professional use in the UK and EU.
Following the approval, the rapid test, for detection of IgG antibodies to the SARS-CoV-2 virus (Covid-19), is now available for distribution for professional use. It is now set to be mass produced, with tests to be rolled out from the end of August 2020.
Abingdon Health is aiming to produce 500,000 Covid-19 antibody tests a month from October and one million a month from January 2021.
The test will be named the 'AbC-19TM Rapid Test'. It uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to send a sample to a lab.
Abingdon Health chief executive Chris Yates said: "This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
"It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test.
"We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible."